Abstract
The COVID-19 pandemic has dramatically impacted global health metrics, with the World Health Organization (WHO) reporting over 732 million cases and 6.7 million deaths by the end of 2021. Additionally, approximately 14.8 million excess deaths were estimated globally through 2022, significantly surpassing reported COVID-19 deaths. In Argentina, recorded pandemic-related fatalities reached nearly 160,000 from March 2020 to December 2022, underlining the necessity for a detailed examination of excess mortality across national and subnational levels.
This study aims to describe excess mortality in Argentina in 2020 and 2021 and its subnational geographic areas, and to identify geographic and temporal disparities across sub-regionsusing publicly available monthly mortality and climate data from Argentina, spanning 2015 to 2021. Excess mortality was assessed using Generalized Additive Models (GAM) to account for long-term and annual trends, monthly climatic variations, and epidemiological reports of Influenza-like Illness (ILI). Data across various geographic regions was analyzed to identify temporal and spatial disparities in mortality.
Our analyses revealed significant regional disparities in mortality, identifying a total of 133,612 excess deaths across Argentina during the study period, with notable peaks coinciding with COVID-19 waves. These insights not only contribute to our understanding of the pandemic’s broader effects but also emphasize the critical need for enhanced public health responses informed by mortality data analyses. The development of an open-source, interactive platform further supports this initiative, enabling detailed exploration and informed decision-making to better manage future public health crises.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was completely supported by the Centro de Implementación e Innovación en Políticas de Salud (CIIPS) at the Instituto de Efectividad Clínica y Sanitaria (IECS), Buenos Aires, Argentina. While CIIPS provided institutional support, no specific grant numbers are applicable as there was no direct external funding allocated specifically for this study. No commercial companies funded the study or the authors, and no salaries or other funding were received from commercial entities in relation to this work. As authors based in a low and middle-income country (LMIC), we would like to request a partial waiver for the publication fees. All aspects of the research were conducted independently by the authors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
N/A
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.